Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.77 |
| ▸ | DRD2 | P14416 | 7/20 | 0.75 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.75 |
| ▸ | HTR1A | P08908 | 6/20 | 0.69 |
| ▸ | HTR2A | P28223 | 6/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.69 |
| ▸ | HTR2C | P28335 | 2/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.67 |
| ▸ | HRH1 | P35367 | 2/20 | 0.67 |
| ▸ | DRD3 | P35462 | 2/20 | 0.67 |
| ▸ | HTR6 | P50406 | 2/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1836420 | 0.97 | ACHE (0.75) | ACHEDRD2SLC6A4HTR1AHTR2A | |
| SCHEMBL6182384 | 0.93 | ACHE (0.80) | ACHEDRD2SLC6A4HTR1AHTR2A | |
| SCHEMBL1545611 | 0.90 | ACHE (0.93) | ACHEDRD2SLC6A4HTR1AHTR2A | |
| SCHEMBL1544799 | 0.88 | ACHE (0.77) | ACHEDRD2SLC6A4HTR2AKCNH2 | |
| SCHEMBL7351897 | 0.88 | ACHE (0.91) | ACHEDRD2SLC6A4HTR1AHTR2A | |
| SCHEMBL791116 | 0.88 | ACHE (0.77) | ACHEDRD2SLC6A4HTR1AHTR2A | |
| SCHEMBL7355656 | 0.88 | ACHE (0.77) | ACHEDRD2SLC6A4HTR1AHTR2A | |
| SCHEMBL1545556 | 0.87 | ACHE (0.75) | ACHEDRD2SLC6A4HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL1544617 | 0.87 | ACHE (0.75) | ACHEDRD2SLC6A4HTR1AHTR2A | |
| SCHEMBL791471 | 0.87 | ACHE (0.75) | ACHEDRD2SLC6A4HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102455329-B | Method for analyzing iloperidone and relevant substances thereof through high performance liquid chromatography (HPLC) | CHONGQING PHARM RES INST CO | 2015-02-25 | — | — | CN | claimed |
| US-20100076196-A1 | PROCESS FOR THE PREPARATION OF ILOPERIDONE | VERTESSY MIKLOS | 2010-03-25 | — | — | US | claimed |
| WO-2010031497-A1 | NEW PROCESS FOR THE PREPARATION OF ILOPERIDONE | MIKLOS VERTESSY (HU) | 2010-03-25 | — | — | WO | claimed |
| EP-4463455-B1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SUVEN LIFE SCIENCES LTD (IN) | 2026-04-29 | — | — | EP | disclosed |
| US-12391698-B2 | Substituted piperidines and piperazines and methods for the treatment of CNS disorders | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-08-19 | — | — | US | disclosed |
| US-12338236-B2 | Benzoisothiazole and benzoisoxazole compounds for the treatment of mental disorders | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-06-24 | — | — | US | disclosed |
| US-20250101014-A1 | BENZOISOTHIAZOLE AND BENZOISOXAZOLE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-03-27 | — | — | US | disclosed |
| US-20250092049-A1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-03-20 | — | — | US | disclosed |
| EP-4469453-A1 | BENZOISOTHIAZOLE AND BENZOISOXAZOLE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS | Suven Life Sciences Limited (IN) | 2024-12-04 | — | — | EP | disclosed |
| EP-4463455-A1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | Suven Life Sciences Limited (IN) | 2024-11-20 | — | — | EP | disclosed |
| CN-118647615-A | Benzisothiazole and benzisoxazole compounds for the treatment of psychotic disorders | 苏文生命科学有限公司 | 2024-09-13 | — | — | CN | disclosed |
| WO-2012063269-A2 | PROCESS FOR PREPARING ILOPERIDONE | CADILA HEALTHCARE LIMITED (IN) | 2012-05-18 | — | — | WO | disclosed |
| US-20100076196-A1 | PROCESS FOR THE PREPARATION OF ILOPERIDONE | VERTESSY MIKLOS | 2010-03-25 | — | — | US | disclosed |
| US-20100076196-A1 | PROCESS FOR THE PREPARATION OF ILOPERIDONE | VERTESSY MIKLOS | 2010-03-25 | — | — | US | disclosed |
| US-20100076196-A1 | PROCESS FOR THE PREPARATION OF ILOPERIDONE | VERTESSY MIKLOS | 2010-03-25 | — | — | US | disclosed |
| US-20100076196-A1 | PROCESS FOR THE PREPARATION OF ILOPERIDONE | VERTESSY MIKLOS | 2010-03-25 | — | — | US | disclosed |
| WO-2010031497-A1 | NEW PROCESS FOR THE PREPARATION OF ILOPERIDONE | MIKLOS VERTESSY (HU) | 2010-03-25 | — | — | WO | disclosed |
| EP-1275641-B1 | Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-01-12 | — | — | EP | disclosed |
| US-6541471-B1 | Useful as a TXA2 receptor antagonist and a 5-HT2 receptor antagonist | LES LABORATOIRES SERVIER (FR) | 2003-04-01 | — | — | US | disclosed |
| EP-1275641-A2 | Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101014-A1 | BENZOISOTHIAZOLE AND BENZOISOXAZOLE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS | GABRA5, GABBR1, GABRA2 | ACHE 855/4885DRD2 426/4885SLC6A4 61/4885 |
| US-12391698-B2 | Substituted piperidines and piperazines and methods for the treatment of CNS disorders | GRIN2C, SLC1A2, CNR2 | ACHE 322/4885DRD2 62/4885SLC6A4 60/4885 |
| US-20100076196-A1 | PROCESS FOR THE PREPARATION OF ILOPERIDONE | IL2, IL17A, IL4 | ACHE 4241/4885DRD2 3537/4885SLC6A4 4609/4885 |
| US-20250092049-A1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | GRIN2C, CNR2, INA | ACHE 175/4885DRD2 249/4885SLC6A4 63/4885 |
| US-12338236-B2 | Benzoisothiazole and benzoisoxazole compounds for the treatment of mental disorders | GABRA5, GABBR1, GABRA2 | ACHE 855/4885DRD2 426/4885SLC6A4 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.